OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Artificial intelligence in drug discovery and development	710
Fsp3: A new parameter for drug-likeness	203
High-Throughput Screening: today’s biochemical and cell-based approaches	171
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management	166
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet	158
Machine-learning methods for ligand–protein molecular docking	143
De novo molecular design and generative models	140
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective	137
Potential SARS-CoV-2 main protease inhibitors	134
Challenges and hopes for Alzheimer’s disease	128
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects	102
Advanced machine-learning techniques in drug discovery	101
Graph neural networks for automated de novo drug design	101
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data	92
Role of reactive oxygen species in the progression of Alzheimer’s disease	90
Drug combination therapy for emerging viral diseases	83
Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors	81
Advances in antibody phage display technology	79
Chloroquine against malaria, cancers and viral diseases	76
Recent advances in targeted nanomedicine as promising antitumor therapeutics	75
Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer	75
Recent advances in metabolomics analysis for early drug development	74
Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory	74
Peptide-based drug discovery: Current status and recent advances	72
Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019	70

Deep learning methods for molecular representation and property prediction	70
AI-based language models powering drug discovery and development	69
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease	67
Leucine as an excipient in spray dried powder for inhalation	67
Stimulus-responsive liposomes for biomedical applications	66
Synthesis and modification of bio-derived antibacterial Ag and ZnO nanoparticles by plants, fungi, and bacteria	64
Obesity and insulin resistance: Pathophysiology and treatment	63
Biochemical pathways of copper complexes: progress over the past 5 years	63
New perspectives in oral peptide delivery	63
Converting peptides into drugs targeting intracellular protein–protein interactions	62
Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods	61
Enhancing preclinical drug discovery with artificial intelligence	60
Folate-mediated one-carbon metabolism: a targeting strategy in cancer therapy	60
m6A RNA methylation and beyond – The epigenetic machinery and potential treatment options	60
Advances in targeting the WNT/β-catenin signaling pathway in cancer	59
PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics	59
The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer	57
Methods to improve the immunogenicity of plasmid DNA vaccines	56
An updated review of folate-functionalized nanocarriers: A promising ligand in cancer	55
Stimuli-responsive hydrogels for intratumoral drug delivery	55
Recent advances in developing polymeric micelles for treating cancer: Breakthroughs and bottlenecks in their clinical translation	54
Utility of Pickering emulsions in improved oral drug delivery	54
3D printing technology as innovative solutions for biomedical applications	54
The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19	53
Advances in the preparation and synthesis of heparin and related products	53
The innovative potential of selenium-containing agents for fighting cancer and viral infections	53
Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems	52
Zebrafish as a model for inflammation and drug discovery	52
Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.	52
Pharmaceutical nanocrystals: A promising approach for improved topical drug delivery	52